Differences and comparisons in efficacy and indications between Elacetrant and Fulvestrant

Elacestrant (Elacestrant) and fulvestrant (Fulvestrant) are both selective estrogen receptor degraders ( SERD), plays an important role in the treatment of breast cancer, especially hormone receptor-positive (HR+), HER2-negative breast cancer. However, there are significant differences between the two in terms of administration methods, efficacy performance, scope of indications, and tolerance. In clinical use, selection needs to be based on patient conditions.

1. Drug mechanism and administration method

Elastrast is an oral small moleculeSERD that inhibits ER-dependent tumor cell proliferation by binding to the estrogen receptor (ER) and inducing its degradation. The characteristics of oral administration make elastran have good patient compliance and convenience, and is particularly suitable for long-term maintenance treatment. In contrast, fulvestrant is an injectable drug that is usually administered monthly or every two weeks through intramuscular injection. It can also effectively degrade ER and block the estrogen signaling pathway. However, the injection method may cause inconvenience to some patients, and there are fluctuations in the maintenance of blood concentration.

2. Clinical efficacy comparison

In terms of efficacy, elastran has shown significant anti-tumor activity in the latest clinical trials in patients with HR+/HER2- advanced breast cancer who have previously failed treatment with aromatase inhibitors (AI) or tamoxifen. Research data shows that elastran can prolong progression-free survival (PFS) and improve overall response rate (ORR), especially for patients carrying ESR1 mutations. As a classic injectable SERD, fulvestrant is equally effective in the treatment of HR+/HER2- advanced and metastatic breast cancer. However, its efficacy in patients with ESR1 mutations is relatively limited. Therefore, in drug-resistant breast cancer, elastran shows certain advantages.

3. Differences in indication scope and clinical application

Fulvestrant is currently approved globally for postmenopausalHR+/HER2- metastatic breast cancer, especially in patients who have failed endocrine therapy, often in combination with CDK4/6 inhibitors. Elastran is mainly targeted at patients with HR+/HER2- advanced breast cancer who have failed endocrine therapy and carry ESR1 mutations. It can be maintained for a long time and can be easily combined with other oral targeted drugs such as CDK4/6 inhibitors or PI3K inhibitors, which expands the treatment options for drug-resistant patients. Generally speaking, the indications of elastran are more focused on people with endocrine resistance or specific gene mutations, while fulvestrant has a relatively broad scope of application.

4. Tolerability and convenience of medication

In terms of tolerability, common adverse reactions of elastrast include nausea, fatigue and mild gastrointestinal reactions, most of which are mild to moderate and can be controlled through dose adjustment or auxiliary medication; the oral administration allows patients to complete treatment in a home environment and reduce the frequency of medical visits. Injection site reactions, mild bone marrow suppression, or hot flashes are common with fulvestrant injection. The discomfort caused by the injection and outpatient dependence may affect long-term compliance. Elastran's oral convenience and specificity for patients with ESR1 mutations make it a strong option in the management of drug-resistant breast cancer.

Generally speaking, elastran and fulvestrant are both SERD drugs that block the growth of breast cancer by degrading estrogen receptors. However, there are significant differences in the mode of administration, efficacy in drug-resistant patients, scope of indications, and convenience of long-term management. Elastran is mainly taken in oral form and is more suitable for patients with ESR1 mutation or drug-resistant breast cancer. It has significant efficacy and high compliance; fulvestrant is in injection form and has a wide range of applications. It is still a common choice after failure of endocrine therapy. Clinicians can develop individualized treatment plans based on the patient's genetic mutation status, tolerance and medication habits to optimize the effect of breast cancer treatment.

Reference link:https://www.drugs.com